This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PDI Announces John L. Parsons Jr. To Lead New Product Commercialization Enterprise, Interpace BioPharma, LLC

PARSIPPANY, N.J., Aug. 1, 2011 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that, effective July 5, John L. Parsons Jr. has been named senior vice president and general manager of Interpace BioPharma, LLC, a new wholly-owned subsidiary formed to manage full product commercialization opportunities, such as the two-and-a-half-year agreement for the sales and marketing of a treatment for knee pain announced separately today.

Before joining Interpace BioPharma, Parsons was president and chief commercial officer of the U.S. division of TopoTarget A/S, a Denmark-based biopharmaceutical company focusing on the research and development of oncology products. Prior to that, Parsons was the founder and president from 2000 to 2006 of Parsons Strategic Associates LLC, a healthcare consulting firm offering strategic, operational, technical, investment and partnership services to emerging and established healthcare and pharmaceutical companies. Parsons was previously at Quintiles, Inc. as vice president, emerging markets, after serving as vice president, market planning.

For approximately 25 years, Parsons held a number of increasingly responsible positions with Knoll Pharmaceutical Company, a unit of BASF Pharma, after first joining as a field sales representative. He left Knoll in 1998 as vice president, sales, after earlier holding positions that included vice president, marketing and sales; director of sales; director of marketing; hospital sales manager; regional manager; and product manager.

Parsons holds a BA in Chemistry from Indiana University, Bloomington, Ind., and has completed programs at Wharton School of Business in Strategic Planning, Finance and Leadership.

About PDI, Inc.

PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with healthcare practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise. For more information, please visit the company's website at


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs